Cancer Treatment Targeting BRCA1-IRIS
OwnerWael M. Elshamyinventor
Life of this patent
Estimating the term…
Abstract
Patients identified as candidates at risk of developing aggressive cancer, including metastatic cancer, are determined based on the expression of BRCA1-IRIS. In one advantageous form, the expression of BRCA1-IRIS is quantified based on BRCA1-IRIS present in tumor cells of patients. The amount of BRCA1-IRIS expression can be quantified in any conventionally known manner, including quantifying the amount of protein present in tumor cells or BRCA1-IRIS mRNA present in tumor cells of patients.
Claims18
A method for identifying risk for developing aggressive cancer in a patient, said method comprising:
- selecting a patient to determine ones risk of developing aggressive cancer;
- acquiring a biological sample from the patient;
- determining the amount of BRCA1-IRIS expression present in the biological sample;
- and
- identifying the patient as a risk candidate for developing aggressive cancer if the amount of BRCA1-IRIS expression exceeds a threshold amount of expression.
A method for detecting expression of BRCA1-IRIS in a patient, the method comprising:
- selecting a patient to determine the amount of BRCA1-IRIS expression;
- acquiring a biological sample from the patient;
- contacting the biological sample with a monoclonal antibody specific for an epitope of BRCA1-IRIS ;
- and
- quantifying the amount of BRCA1-IRIS present in the sample based on an amount of the antibody bound BRCA1-IRIS.
A method for detecting expression of BRCA1-IRIS in a patient, the method comprising:
- selecting a patient to determine the amount of BRCA1-IRIS expression;
- acquiring a biological sample from the patient;
- extracting mRNA from the biological sample;
- conducting PCR on the mRNA in the biological sample using specific 5′ and 3′ primers for BRCA1-IRIS;
- and
- quantifying the amount of BRAC1-IRIS mRNA based on PCR product to determine the amount of BRAC1-IRIS expression.
A method for reducing the growth or proliferation of cancer cells, the method comprising administering a therapeutically effective amount of an inhibitor of BRCA1-IRIS, to cancer cells, to thereby reduce the growth or proliferation of the cancer cells.
Dependencies are inferred from the claim text.